US-based biotechnology firm Signum Dermalogix has out-licensed SIG990, a new anti-inflammatory compound, to Dermata Therapeutics for the development of a topical product to treat patients with rosacea, a chronic skin condition.
SIG990 is claimed to have the potential to both reduce erythema and decrease the papules and pustules associated with the disease.
The company has already secured approval for its investigational new drug (IND) application for SIG990 from the US Food and Drug Administration (FDA).
As part of the deal, Dermata has secured an exclusive worldwide license to SIG990 and is also responsible for the clinical development of the product.
In addition, Dermalogix is also eligible to receive milestone payments and royalties on revenues of the product.
Signum Dermalogix CEO Maxwell Stock said: “We are excited to partner with Dermata and look forward to working with their experienced team to advance SIG990 in the clinic.
“Partnering allows us to share expertise and thereby provides an effective way of progressing cutting edge research and development. I’d also like to thank the National Institute of Allergy and Infectious Diseases (NIAID) for their support in helping fund this drug development program.”
In the US, rosacea affects between 16-20 million people and typically appears during ages 30 to 40, primarily in women.
Dermata acting CEO David Hale said: “We believe that this first-in-class compound SIG990 has the potential to be a significant treatment option for patients with rosacea.
“This disease, while not life-threatening, can have a serious impact on the quality of life of patients. We are excited about moving SIG990 into patients in a Phase II clinical trial.”